Ask AI
ProCE Banner Activity

Advancing the Early Detection of Lung Cancer: Improving Awareness and Implementation of Low-Dose CT Screening

Clinical Thought

This expert commentary discusses insights gained from our educational program addressing low-dose CT screening for the early detection of lung cancer. Despite the substantial burden of lung cancer in the United States, use of low-dose CT screening among eligible individuals remains low. Experts examine current eligibility criteria, strategies to improve screening among underserved populations, and emerging approaches to lung cancer risk assessment and detection. They also consider patients who do not clearly meet current USPSTF screening criteria but may be at higher risk for lung cancer, including how additional risk factors may inform decisions about low-dose CT screening.

Released: October 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

Lilly

Merck Sharp & Dohme, LLC

Target Audience

This activity has been designed to meet the educational needs of primary care providers, nurse practitioners, physician associates, nurses, and other healthcare professionals who care for patients at high risk for developing lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Initiate low-dose CT screening in all eligible patients at risk of lung cancer to improve clinical outcomes in patients with lung cancer

  • Identify factors impeding the broad use of low-dose CT screening for lung cancer in clinical practice

  • Screen patients in underserved populations at risk for developing lung cancer using low-dose CT to improve early detection and treatment of lung cancer

  • Communicate the importance of screening for lung cancer with low-dose CT with patients at risk of lung cancer to facilitate adherence to screening recommendations

Financial Disclosures

Primary Author

Brendon M. Stiles, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Intuitive, Medtronic, Merck/MSD, Regeneron, Roche/Genentech; researcher: Bristol Myers Squibb, Bristol Myers Squibb Foundation, Merck/MSD.

Julie T. Wu, MD, PhD, has no relevant financial relationships to disclose.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.